Nordion said that a phase II clinical trial showed that its TheraSphere therapeutic radiopharmaceutical provides safe and well-tolerated treatment for patients with liver metastases.
In a preliminary analysis presented Sunday at the Society of Interventional Radiology (SIR) annual meeting in Chicago, researchers from Northwestern University found that overall tumor response -- including stable disease -- was 90% in metastatic neuroendocrine tumors and 69.2% in all treatment groups.
Treatment was also judged to be well tolerated and achieved consistent results across all five participating centers in the study, according to Nordion. The multisite trial ran from 2007 to 2011 and involved 151 patients.
